Cantor Fitzgerald Estimates AARD FY2024 Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – Equities researchers at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Aardvark Therapeutics in a report issued on Monday, March 10th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of ($3.89) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $50.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Aardvark Therapeutics’ FY2025 earnings at ($2.49) EPS.

A number of other analysts also recently weighed in on the stock. Bank of America began coverage on shares of Aardvark Therapeutics in a report on Monday. They issued a “buy” rating and a $22.00 price target for the company. Royal Bank of Canada assumed coverage on Aardvark Therapeutics in a research report on Monday. They issued an “outperform” rating and a $21.00 price objective for the company. Finally, Morgan Stanley began coverage on shares of Aardvark Therapeutics in a research report on Monday. They set an “overweight” rating and a $29.00 target price on the stock.

Aardvark Therapeutics Stock Performance

Shares of Aardvark Therapeutics stock opened at $10.14 on Wednesday. Aardvark Therapeutics has a 1 year low of $9.21 and a 1 year high of $19.58.

Insiders Place Their Bets

In other Aardvark Therapeutics news, CEO Tien-Li Lee acquired 16,542 shares of Aardvark Therapeutics stock in a transaction on Friday, February 14th. The shares were bought at an average price of $16.00 per share, with a total value of $264,672.00. Following the completion of the purchase, the chief executive officer now owns 1,496,175 shares in the company, valued at $23,938,800. This trade represents a 1.12 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Nelson Sun bought 10,000 shares of the stock in a transaction dated Friday, February 14th. The stock was acquired at an average price of $16.00 per share, with a total value of $160,000.00. Following the completion of the purchase, the chief financial officer now owns 99,484 shares of the company’s stock, valued at $1,591,744. This represents a 11.18 % increase in their position. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.